ARCHIVES

Study: CYP2D6 Genotypes Are Unreliable Predictors of Benefit

This article is from The Cancer Letter archive.

Vol. 35 No. 3 | March 30, 2012

Download PDF Visit The Full Archive

Related Articles

Ovarian Suppression Treatment Plus Tamoxifen Can Lower Recurrence Risk

December 26, 2014

Institute Of Medicine Report Says Insurers Should Pay Patient Care Costs In Clinical Trials

February 24, 1989

Holland, Hoogstraten Give Up Chairmanships Of CALGB, SWOG

March 6, 1981

ASCO 2012: Michael Link’s Presidential Address, and the 2012 Award Winners

June 8, 2012

NCCS Networker Volume 3 Issue 4, Fall 1989

September 13, 1989

Panel Angered By Unreasonable Senate Committee Demands, Will Seek Meeting With Hatch On Probe

April 24, 1981